NCT03937154 2026-01-27Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast CancerAmgenPhase 3 Active not recruiting145 enrolled
NCT01444417 2017-02-09Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric PatientsAmgenPhase 3 Completed62 enrolled 16 charts 1 FDA
NCT00515203 2014-07-25Safety and Efficacy Study of Romiplostim (AMG 531) to Treat ITP in Pediatric SubjectsAmgenPhase 1/2 Completed22 enrolled 13 charts 1 FDA
NCT00413283 2013-10-24Dose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer (NSCLC)AmgenPhase 2 Completed63 enrolled 15 charts
NCT00283439 2011-06-20A Dose and Schedule Finding Trial With AMG 531 for Chemotherapy Induced Thrombocytopenia (CIT) in Adults With LymphomaAmgenPhase 1/2 Completed39 enrolled 13 charts